Renal Cell Carcinoma | Clinical

Lee Reviews Trials Supporting IO/TKI Combinations in Frontline RCC

September 23, 2022

During a Targeted Oncology case-based roundtable event, Chung-Han Lee, MD, PhD, discussed the latest data supporting the use of lenvatinib/pembrolizumab as frontline therapy for patients with advanced clear cell renal cell carcinoma.